Teva Pharmaceutical Industries Ltd (TEVA) KPIs and segments
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Teva Pharmaceutical Industries · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Teva Pharmaceutical Industries: 61 chỉ số vận hành, trong đó có Consolidated Net Revenues, AUSTEDO (deutetrabenazine) — Global Revenues và AJOVY (fremanezumab) — Global Revenues, lấy từ 162 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States($M)9 | 1,702 | 1,534 | 2,643 | 2,483 | 1,786 | 1,536 | 1,974 | 2,225 | 2,110 | 1,725 | 2,266 | ||
AUSTEDO($M) | 676 | 559 | 725 | 601 | 495 | 396 | 518 | 435 | 407 | 282 | 408 | ||
Generic products (including OTC and biosimilars)($M) | 660 | 612 | 673 | 1,175 | 961 | 849 | 675 | 1,094 | 1,023 | 808 | |||
Anda($M) | 366 | 392 | 365 | 373 | 402 | 380 | 373 | 381 | 394 | ||||
AJOVY($M) | 116 | 87 | 105 | 73 | 63 | 53 | 63 | 58 | 42 | 45 | 57 | ||
Other($M) | 84 | 123 | 608 | 101 | 111 | 109 | 171 | 115 | 119 | 117 | 608 | ||
UZEDY($M) | 77 | 63 | 55 | 43 | 54 | 39 | 42 | 35 | 24 | 15 | 9 | ||
COPAXONE($M) | 61 | 62 | 76 | 62 | 62 | 54 | 63 | 69 | 81 | 30 | 73 | ||
BENDEKA and TREANDA($M) | 28 | 27 | 36 | 35 | 40 | 36 | 41 | 40 | 41 | 46 | 52 | ||
Generic products($M) | 1,094 | 1,023 | 808 | ||||||||||
Europe($M)6 | 1,263 | 1,340 | 1,314 | 1,235 | 1,298 | 1,194 | 1,354 | 1,265 | 1,213 | 1,272 | 1,344 | ||
Generic products (including OTC and biosimilars)($M) | 1,024 | 1,089 | 1,033 | 982 | 1,040 | 989 | 979 | 973 | 970 | 1,004 | |||
AJOVY($M) | 78 | 76 | 75 | 66 | 71 | 58 | 58 | 56 | 52 | 51 | 45 | ||
Respiratory Product($M) | 58 | 59 | 65 | 52 | 55 | 55 | 61 | 60 | 57 | 66 | 70 | ||
Other($M) | 54 | 76 | 96 | 91 | 81 | 50 | 205 | 124 | 81 | 94 | 234 | ||
COPAXONE($M) | 49 | 40 | 46 | 44 | 50 | 42 | 50 | 53 | 53 | 57 | 57 | ||
Generic products($M) | 973 | 970 | 1,004 | 937 | |||||||||
Other Activities($M)4 | 627 | 584 | 226 | 205 | 597 | 579 | 241 | 229 | 249 | 225 | 245 | ||
Distribution($M) | 413 | 378 | 0 | 0 | 365 | 373 | 0 | 0 | 0 | 0 | 0 | ||
Sale of Goods($M) | 118 | 109 | 137 | 125 | 136 | 129 | 154 | 121 | 150 | 128 | 153 | ||
Other($M) | 95 | 97 | 88 | 78 | 98 | 76 | 85 | 100 | 99 | 97 | 92 | ||
Licensing Arrangements($M) | 1 | 3 | -1 | 1 | 1 | 8 | 1 | 1 | |||||
International Markets($M)9 | 550 | 524 | 528 | 557 | 495 | 582 | 661 | 613 | 593 | 597 | 601 | ||
Sale of Goods($M) | 527 | 476 | 504 | 512 | 469 | 553 | 572 | 568 | 574 | 566 | 573 | ||
Generic products (including OTC and biosimilars)($M) | 419 | 386 | 423 | 421 | 410 | 468 | 497 | 477 | 486 | 477 | |||
AJOVY($M) | 49 | 33 | 30 | 30 | 20 | 28 | 21 | 24 | 22 | 17 | 18 | ||
Distribution($M) | 20 | 18 | 18 | 14 | 12 | 11 | 11 | 10 | 9 | 9 | 9 | ||
AUSTEDO($M) | 20 | 19 | 9 | 17 | 3 | 15 | 7 | 13 | 12 | 14 | |||
COPAXONE($M) | 8 | 6 | 7 | 8 | 7 | 10 | 10 | 13 | 14 | 12 | 13 | ||
Licensing Arrangements($M) | 7 | 8 | 8 | 5 | 9 | 6 | 7 | 6 | 6 | 5 | 7 | ||
Other($M) | -3 | 22 | 60 | 26 | 5 | 12 | 72 | 29 | 4 | 16 | 13 | ||
Generic products($M) | 477 | 486 | 477 | 169 | |||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Sale of Goods($M)3 | 3,602 | 3,389 | 3,668 | 3,907 | 3,636 | 3,395 | 3,418 | 3,725 | 3,640 | 3,267 | 3,255 | ||
United States($M) | 1,704 | 1,493 | 1,749 | 2,063 | 1,755 | 1,514 | 1,470 | 1,822 | 1,714 | 1,321 | 1,344 | ||
Europe($M) | 1,253 | 1,312 | 1,278 | 1,207 | 1,275 | 1,198 | 1,223 | 1,214 | 1,203 | 1,252 | 1,185 | ||
North America($M) | 1,444 | ||||||||||||
Distribution($M)3 | 433 | 396 | 384 | 406 | 377 | 384 | 413 | 390 | 382 | 391 | 403 | ||
United States($M) | 0 | 0 | 366 | 392 | 0 | 0 | 402 | 380 | 373 | 381 | 394 | ||
Europe($M) | 0 | ||||||||||||
North America($M) | 394 | ||||||||||||
Other($M)2 | 70 | 157 | 109 | 121 | 117 | 76 | 346 | 172 | 106 | 121 | 252 | ||
Europe($M) | -3 | 18 | 23 | 16 | 13 | -12 | 122 | 42 | 3 | 9 | 147 | ||
United States($M) | -19 | 20 | 1 | 2 | 1 | ||||||||
Licensing Arrangements($M)3 | 37 | 39 | 550 | 46 | 46 | 36 | 52 | 45 | 36 | 40 | 547 | ||
United States($M) | 17 | 21 | 529 | 27 | 29 | 22 | 35 | 23 | 23 | 23 | 525 | ||
Europe($M) | 13 | 10 | 12 | 11 | 9 | 7 | 9 | 9 | 6 | 11 | 13 | ||
North America($M) | 526 | ||||||||||||
United States($M) | 1,702 | 1,534 | 2,643 | 2,483 | 1,786 | 1,536 | 1,974 | 2,225 | 2,110 | 1,725 | 2,266 | ||
Europe($M) | 1,263 | 1,340 | 1,314 | 1,235 | 1,298 | 1,194 | 1,354 | 1,265 | 1,213 | 1,272 | 1,344 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Corporate Segment($M) | 391 | 972 | 1,558 | 1,334 | 1,136 | 944 | 1,148 | 1,230 | 1,043 | 890 | 1,544 | ||
Europe($M) | 367 | 401 | 307 | 303 | 364 | 329 | 438 | 373 | 342 | 423 | 461 | ||
International Markets($M) | 99 | 65 | 70 | 95 | 74 | 97 | 141 | 109 | 73 | 117 | 109 | ||
Other Segments($M) | -16 | -16 | -26 | -40 | -3 | 2 | 19 | -16 | 12 | 2 | 2 | ||
United States($M) | -76 | 507 | 1,181 | 937 | 699 | 518 | 569 | 748 | 629 | 350 | 973 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
United States($M) | 1,203 | 1,038 | 1,823 | 1,487 | 1,212 | 1,013 | 1,097 | 1,265 | 1,167 | 858 | |||
Europe($M) | 704 | 734 | 708 | 665 | 717 | 658 | 794 | 698 | 677 | 738 | 783 | ||
International Markets($M) | 284 | 244 | 247 | 277 | 244 | 278 | 346 | 306 | 286 | 297 | 189 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Consolidated Net Revenues($M)3 | 4,395 | 4,142 | 3,982 | 1,500 | 4,480 | 4,176 | 3,891 | 4,229 | 4,332 | 4,164 | 3,819 | 4,457 | |
Consolidated Revenues — Reported YoY Change(%) | -2.0% | -1.0% | 2.0% | 11.0% | 3.0% | 2.0% | 13.0% | 7.0% | 4.0% | 15.0% | |||
Consolidated Revenues — Local Currency YoY Change(%) | -2.0% | -3.0% | -3.0% | 9.0% | 1.0% | 5.0% | 15.0% | 11.0% | 5.0% | 14.0% | |||
Share of Consolidated Revenues in Non-U.S. Dollar Currencies(%) | 46.0% | 47.0% | 48.0% | 43.0% | 45.0% | 46.0% | 48.0% | 47.0% | 47.0% | 48.0% | 50.0% | 47.0% | |
AUSTEDO (deutetrabenazine) — Global Revenues($M)3 | 751 | 696 | 578 | ||||||||||
AUSTEDO Global Revenues — Local Currency YoY Growth(%) | 21.0% | 40.0% | 41.0% | ||||||||||
AUSTEDO — United States Segment Revenues($M)2 | 727 | 676 | 559 | 725 | 601 | 495 | 396 | 518 | 435 | 407 | 282 | 408 | |
AUSTEDO (U.S.) — Reported YoY Change(%) | 21.0% | 37.0% | 41.0% | 40.0% | 38.0% | 22.0% | 40.0% | 27.0% | 28.0% | 32.0% | 67.0% | ||
AUSTEDO — Legacy North America Segment Revenues (FY2016–FY2023)($M)1 | 408 | ||||||||||||
AUSTEDO (Legacy North America) — Reported YoY Change(%) | 18.0% | ||||||||||||
AUSTEDO — International Markets Segment Revenues($M)1 | 24 | 20 | 19 | 9 | 17 | 3 | 15 | 7 | 13 | 12 | 14 | 5 | |
AUSTEDO (International Markets) — Reported YoY Change(%) | 42.0% | 571.0% | 30.0% | 29.0% | 32.0% | -76.0% | 4.0% | 50.0% | 28.0% | 32.0% | 67.0% | ||
AJOVY (fremanezumab) — Global Revenues($M)5 | 269 | 244 | 196 | ||||||||||
AJOVY Global Revenues — Local Currency YoY Growth(%) | 61.0% | 56.0% | 35.0% | ||||||||||
AJOVY — U.S. Anti-CGRP Subcutaneous Exit Prescription Market Share (IQVIA)(%) | 32.8% | 32.5% | 32.0% | 31.0% | 29.6% | 28.6% | |||||||
AJOVY — United States Segment Revenues($M)2 | 138 | 116 | 87 | 105 | 73 | 63 | 53 | 63 | 58 | 42 | 45 | 57 | |
AJOVY (U.S.) — Reported YoY Change(%) | 88.0% | 83.0% | 64.0% | 68.0% | 27.0% | 53.0% | 18.0% | 11.0% | 4.0% | -20.0% | -3.0% | ||
AJOVY — Legacy North America Segment Revenues (FY2018–FY2023)($M)1 | 62 | ||||||||||||
AJOVY (Legacy North America) — Reported YoY Change(%) | 17.0% | ||||||||||||
AJOVY — Europe Segment Revenues($M)2 | 84 | 78 | 76 | 75 | 66 | 71 | 58 | 58 | 56 | 52 | 51 | 45 | |
AJOVY (Europe) — Reported YoY Change(%) | 28.0% | 10.0% | 31.0% | 30.0% | 18.0% | 38.0% | 14.0% | 28.0% | 37.0% | 33.0% | 42.0% | 31.0% | |
AJOVY (Europe) — Local Currency YoY Change(%) | 29.0% | 7.0% | 17.0% | 28.0% | |||||||||
AJOVY — International Markets Segment Revenues($M)2 | 48 | 49 | 33 | 30 | 30 | 20 | 28 | 21 | 24 | 22 | 17 | 18 | |
AJOVY (International Markets) — Reported YoY Change(%) | 61.0% | 146.0% | 20.0% | 40.0% | 23.0% | -7.0% | 65.0% | 16.0% | 35.0% | 58.0% | 26.0% | ||
AJOVY (International Markets) — Local Currency YoY Change(%) | 61.0% | 141.0% | 15.0% | ||||||||||
UZEDY (risperidone LAI) — United States Segment Revenues($M)1 | 85 | 77 | 63 | 55 | 43 | 54 | 39 | 42 | 35 | 24 | 15 | 9 | |
UZEDY (U.S.) — Reported YoY Change(%) | 96.0% | 43.0% | 62.0% | 28.0% | 24.0% | 120.0% | 156.0% | ||||||
U.S. Generic Prescriptions Dispensed — Trailing Twelve Months (IQVIA)(M)1 | 227 | 237 | 246 | 254 | 261 | 266 | 273 | 68 | 292 | 303 | 314 | 78 | |
U.S. Generic Prescription Market Share (IQVIA)(%) | 5.8% | 6.1% | 6.3% | 6.5% | 6.7% | 6.9% | 7.1% | 6.9% | 7.6% | 8.4% | 8.2% | 8.0% | |
Generic Products (incl. Biosimilars & OTC) — United States Segment Revenues($M)2 | 718 | 660 | 612 | 673 | 1,175 | 961 | 849 | 675 | 1,094 | 1,023 | 808 | 667 | |
U.S. Generic Products — Reported YoY Change(%) | 39.0% | -31.0% | -28.0% | 7.0% | -6.0% | 5.0% | 1.0% | 30.0% | 16.0% | 8.0% | |||
Generic Products — Legacy North America Segment Revenues (FY2016–FY2023)($M)1 | 753 | ||||||||||||
Legacy North America Generic Products — Reported YoY Change(%) | -8.0% | ||||||||||||
Generic Products (incl. OTC & Biosimilars) — Europe Segment Revenues($M)1 | 1,033 | 1,024 | 1,089 | 1,033 | 982 | 1,040 | 989 | 979 | 973 | 970 | 1,004 | 937 | |
Europe Generic Products — Reported YoY Change(%) | 5.0% | -2.0% | 10.0% | 5.0% | 1.0% | 7.0% | -1.0% | 4.0% | 10.0% | 7.0% | 8.0% | 3.0% | |
Generic Products (incl. OTC & Biosimilars) — International Markets Segment Revenues($M)1 | 407 | 419 | 386 | 423 | 421 | 410 | 468 | 497 | 477 | 486 | 477 | 507 | |
International Markets Generic Products — Reported YoY Change(%) | 3.0% | 2.0% | -18.0% | -15.0% | -12.0% | -16.0% | -2.0% | -2.0% | 1.0% | 2.0% | 8.0% | 2.0% | |
COPAXONE (glatiramer acetate) — United States Segment Revenues($M)4 | 58 | 61 | 62 | 76 | 62 | 62 | 54 | 63 | 69 | 81 | 30 | 73 | |
COPAXONE (U.S.) — Reported YoY Change(%) | 8.0% | -2.0% | 16.0% | 22.0% | -9.0% | -23.0% | 79.0% | -13.0% | -30.0% | 44.0% | -58.0% | ||
COPAXONE — Legacy North America Segment Revenues (FY2016–FY2023)($M)1 | 78 | ||||||||||||
COPAXONE (Legacy North America) — Reported YoY Change(%) | 24.0% | ||||||||||||
COPAXONE — Europe Segment Revenues($M)2 | 38 | 49 | 40 | 46 | 44 | 50 | 42 | 50 | 53 | 53 | 57 | 57 | |
COPAXONE (Europe) — Reported YoY Change(%) | 12.0% | -2.0% | -4.0% | -9.0% | -18.0% | -6.0% | -27.0% | -11.0% | -5.0% | -11.0% | -4.0% | 8.0% | |
COPAXONE (Europe) — Local Currency YoY Change(%) | -11.0% | -5.0% | -14.0% | -17.0% | -23.0% | -11.0% | -24.0% | -11.0% | -5.0% | -9.0% | |||
COPAXONE — International Markets Segment Revenues($M)1 | 8 | 8 | 6 | 7 | 8 | 7 | 10 | 10 | 13 | 14 | 12 | 13 | |
COPAXONE (International Markets) — Reported YoY Change(%) | 8.0% | 7.0% | -43.0% | -31.0% | -40.0% | -50.0% | -11.0% | -25.0% | -18.0% | -20.0% | -32.0% | ||
BENDEKA and TREANDA (bendamustine) — United States Segment Revenues($M)2 | 30 | 28 | 27 | 36 | 35 | 40 | 36 | 41 | 40 | 41 | 46 | 52 | |
BENDEKA and TREANDA (U.S.) — Reported YoY Change(%) | 15.0% | 30.0% | -26.0% | -13.0% | -3.0% | -20.0% | -21.0% | -28.0% | -39.0% | 26.0% | |||
BENDEKA and TREANDA — Legacy North America Segment Revenues (FY2016–FY2023)($M)1 | 53 | ||||||||||||
BENDEKA and TREANDA (Legacy North America) — Reported YoY Change(%) | -29.0% | ||||||||||||
Respiratory Products — Europe Segment Revenues($M)2 | 54 | 58 | 59 | 65 | 52 | 55 | 55 | 61 | 60 | 57 | 66 | 70 | |
Respiratory Products (Europe) — Reported YoY Change(%) | 3.0% | 6.0% | 8.0% | 6.0% | -13.0% | -3.0% | -18.0% | -13.0% | -1.0% | -14.0% | -3.0% | 7.0% | |
Respiratory Products (Europe) — Local Currency YoY Change(%) | 4.0% | 3.0% | -2.0% | -2.0% | -18.0% | -8.0% | -16.0% | -13.0% | -3.0% | -13.0% | |||
U.S. Generic Pipeline — Product Applications (ANDAs) Awaiting FDA Approval5 | 96 | 101 | 112 | 116 | 123 | 128 | 130 | 127 | 125 | 126 | 130 | 137 | |
U.S. Generic Tentative FDA Approvals (Included in Pending ANDAs) | 56 | 59 | 65 | 66 | 68 | 69 | 68 | 65 | 62 | 60 | 61 | 63 | |
U.S. First-to-File (Paragraph IV) Pending Generic Products | 45 | 48 | 53 | 54 | 55 | 55 | 56 | 54 | 55 | 56 | 59 | 62 | |
U.S. First-to-File Generic Products (Including Final Approvals Pending Launch) | 73 | 71 | 76 | 77 | 80 | 81 | 84 | 82 | 85 | 85 | 86 | 88 | |
Share of Pending U.S. ANDAs Challenging Brand Patents (Paragraph IV)(%) | 79.0% | 80.0% | 81.0% | 80.0% | 74.0% | 74.0% | 75.0% | 78.0% | 79.0% | 79.0% | 78.0% | 78.0% | |
Annual U.S. Branded Market Value of Pending ANDAs (IQVIA) | 93.00 | 102.00 | 128.00 | 124.00 | 123.00 | 128.00 | 124.00 | 122.00 | 119.00 | 112.00 | 111.00 | 107.00 | |
Europe Generic Pipeline — Pending Marketing Authorization Applications (MAAs)6 | 1,329 | 1,426 | 1,408 | 1,548 | 1,490 | 1,508 | 1,508 | 1,423 | 1,470 | ||||
Europe Countries with Pending Generic MAAs | 37 | 37 | 37 | 37 | 37 | 37 | 37 | 37 | 37 | ||||
Europe Pending Generic MAAs — Distinct Compounds | 100 | 99 | 94 | 95 | 97 | 93 | 94 | 98 | 101 | ||||
Europe Pending Generic MAAs — Formulations | 221 | 225 | 215 | 216 | 215 | 219 | 215 | 212 | 223 | ||||
Europe Generic Marketing Approvals Received (Cumulative YTD / Full Year) | 358 | 267 | 89 | 622 | 496 | 273 | 128 | 686 | 412 | 280 | 132 | 442 | |
Europe Generic Approvals Received — Distinct Compounds | 43 | 33 | 19 | 61 | 42 | 30 | 16 | 71 | 53 | 44 | 25 | 67 | |
Europe Generic Approvals Received — Formulations | 95 | 74 | 47 | 125 | 87 | 67 | 35 | 149 | 108 | 81 | 47 | 124 | |
Contingent Consideration Liabilities — Fair Value Balance (R&D & Acquisition Milestones)($M)1 | 43 | 49 | 40 | 51 | 198 | 303 | 394 | 401 | 552 | 656 | 567 | 517 | |
Change in Fair Value of Contingent Consideration($M) | 2 | 17 | 5 | 8 | 16 | 19 | 11 | -2 | 34 | 192 | 79 | 408 | |
United States Segment — Total Revenues($M)13 | 1,870 | 1,702 | 1,534 | 3,773 | 2,090 | 1,786 | 1,536 | 1,974 | 2,225 | 2,110 | 1,725 | 2,266 | |
United States Segment Other Products — Reported YoY Change(%) | 13.0% | -25.0% | 13.0% | 255.0% | -13.0% | -7.0% | -7.0% | -72.0% | -18.0% | 9.0% | -16.0% | ||
United States Segment — Cost of Sales($M) | 467 | 499 | 496 | 1,826 | 645 | 574 | 523 | 877 | 960 | 943 | 867 | 822 | |
United States Segment — Cost of Sales (% of Segment Revenues)(%) | 25.0% | 29.3% | 32.3% | 31.0% | 40.1% | 41.9% | 44.6% | 44.4% | 43.1% | 44.7% | 50.2% | 36.3% | |
United States Segment — Gross Profit Margin (% of Segment Revenues)(%) | 75.0% | 70.7% | 67.7% | 69.0% | 59.9% | 58.1% | 55.4% | 55.6% | 56.9% | 55.3% | 49.8% | 63.7% | |
United States Segment — R&D Expenses($M) | 196 | 883 | 147 | 166 | 161 | 152 | 154 | 158 | 151 | 170 | 154 | 144 | |
United States Segment — R&D Expenses (% of Segment Revenues)(%) | 10.5% | 51.9% | 9.6% | 6.3% | 6.5% | 7.0% | 8.1% | 8.0% | 6.8% | 8.1% | 8.9% | 6.3% | |
United States Segment — S&M Expenses($M) | 306 | 294 | 298 | 431 | 248 | 250 | 244 | 260 | 259 | 270 | 261 | 238 | |
United States Segment — S&M Expenses (% of Segment Revenues)(%) | 16.4% | 17.3% | 19.4% | 12.9% | 11.2% | 13.0% | 14.3% | 13.2% | 11.6% | 12.8% | 15.1% | 10.5% | |
United States Segment — G&A Expenses($M) | 109 | 107 | 90 | 139 | 113 | 111 | 95 | 110 | 107 | 100 | 93 | 89 | |
United States Segment — G&A Expenses (% of Segment Revenues)(%) | 5.9% | 6.3% | 5.9% | 5.1% | 4.6% | 5.2% | 5.0% | 5.5% | 4.8% | 4.7% | 5.4% | 4.0% | |
United States Segment — Other Operating Income / (Expense)($M) | 0 | -5 | -4 | -3 | 0 | 3 | 1 | 0 | -1 | 1 | -2 | ||
United States Segment — Segment Profit Margin (% of Segment Revenues)(%) | 42.3% | 4.5% | 33.0% | 44.7% | 37.7% | 32.8% | 27.9% | 28.8% | 33.6% | 29.8% | 20.3% | 43.0% | |
United States Segment — Depreciation Expense($M) | 39 | 36 | 36 | 37 | 37 | 36 | |||||||
Europe Segment — Total Revenues($M)14 | 1,319 | 1,263 | 1,340 | 1,314 | 1,235 | 1,298 | 1,194 | 1,354 | 1,265 | 1,213 | 1,272 | 1,344 | |
Europe Segment Revenues — Reported YoY Change(%) | 7.0% | -3.0% | 12.0% | -3.0% | -2.0% | 7.0% | -6.0% | 1.0% | 10.0% | 4.0% | 7.0% | 19.0% | |
Europe Segment Revenues — Local Currency YoY Change(%) | 7.0% | -8.0% | -1.0% | 10.0% | |||||||||
Europe Segment Other Products — Reported YoY Change(%) | 21.0% | -34.0% | 52.0% | -53.0% | -26.0% | 1.0% | -46.0% | -12.0% | 19.0% | -10.0% | 6.0% | 443.0% | |
Europe Segment — Cost of Sales($M) | 562 | 559 | 606 | 606 | 570 | 581 | 536 | 560 | 566 | 536 | 534 | 561 | |
Europe Segment — Cost of Sales (% of Segment Revenues)(%) | 42.6% | 44.3% | 45.2% | 46.1% | 46.1% | 44.8% | 44.9% | 41.4% | 44.8% | 44.2% | 42.0% | 41.7% | |
Europe Segment — Gross Profit Margin (% of Segment Revenues)(%) | 57.4% | 55.7% | 54.8% | 53.9% | 53.9% | 55.2% | 55.1% | 58.6% | 55.2% | 55.8% | 58.0% | 58.3% | |
Europe Segment — R&D Expenses($M) | 62 | 52 | 45 | 66 | 62 | 59 | 60 | 56 | 55 | 62 | 56 | 52 | |
Europe Segment — R&D Expenses (% of Segment Revenues)(%) | 4.7% | 4.1% | 3.4% | 5.0% | 5.0% | 4.6% | 5.1% | 4.2% | 4.3% | 5.1% | 4.4% | 3.9% | |
Europe Segment — S&M Expenses($M) | 211 | 222 | 215 | 250 | 225 | 228 | 199 | 221 | 203 | 209 | 194 | 202 | |
Europe Segment — S&M Expenses (% of Segment Revenues)(%) | 16.0% | 17.6% | 16.0% | 19.0% | 18.2% | 17.5% | 16.7% | 16.3% | 16.0% | 17.2% | 15.2% | 15.1% | |
Europe Segment — G&A Expenses($M) | 64 | 66 | 73 | 85 | 75 | 66 | 69 | 75 | 67 | 64 | 65 | 67 | |
Europe Segment — G&A Expenses (% of Segment Revenues)(%) | 4.8% | 5.2% | 5.4% | 6.4% | 6.1% | 5.1% | 5.8% | 5.6% | 5.3% | 5.3% | 5.1% | 5.0% | |
Europe Segment — Segment Profit Margin (% of Segment Revenues)(%) | 31.8% | 29.1% | 29.9% | 23.4% | 24.5% | 28.0% | 27.6% | 32.4% | 29.5% | 28.2% | 33.2% | 34.3% | |
Europe Segment — Depreciation Expense($M) | 33 | 33 | 33 | 31 | 31 | 30 | |||||||
International Markets Segment — Total Revenues($M)15 | 592 | 550 | 524 | 528 | 557 | 495 | 582 | 661 | 613 | 593 | 597 | 601 | |
International Markets Segment Revenues — Reported YoY Change(%) | 6.0% | 11.0% | -10.0% | -20.0% | -9.0% | -17.0% | -2.0% | 10.0% | 4.0% | 3.0% | 3.0% | 4.0% | |
International Markets Segment Revenues — Local Currency YoY Change(%) | 4.0% | 7.0% | -19.0% | -20.0% | -10.0% | -16.0% | 5.0% | 17.0% | 18.0% | 22.0% | 17.0% | 22.0% | |
International Markets Segment — Other Products & Distribution Revenue($M) | 105 | 55 | 79 | 60 | 82 | 55 | 61 | 127 | 86 | 59 | 77 | 49 | |
International Markets Other Products — Reported YoY Change(%) | 28.0% | -1.0% | 30.0% | -52.0% | -4.0% | -6.0% | -21.0% | 112.0% | 14.0% | 2.0% | 24.0% | 23.0% | |
International Markets Segment — Cost of Sales($M) | 276 | 266 | 280 | 281 | 280 | 251 | 304 | 315 | 307 | 307 | 300 | 302 | |
International Markets Segment — Cost of Sales (% of Segment Revenues)(%) | 46.7% | 48.3% | 53.6% | 53.1% | 50.2% | 50.8% | 52.3% | 47.7% | 50.1% | 51.7% | 50.3% | 50.2% | |
International Markets Segment — Gross Profit Margin (% of Segment Revenues)(%) | 53.3% | 51.7% | 46.4% | 46.9% | 49.8% | 49.2% | 47.7% | 52.3% | 49.9% | 48.3% | 49.7% | 54.3% | |
International Markets Segment — R&D Expenses($M) | 31 | 26 | 22 | 28 | 26 | 24 | 25 | 27 | 27 | 30 | 28 | 23 | |
International Markets Segment — R&D Expenses (% of Segment Revenues)(%) | 5.3% | 4.8% | 4.3% | 5.2% | 4.6% | 4.9% | 4.3% | 4.1% | 4.4% | 5.1% | 4.6% | 3.9% | |
International Markets Segment — S&M Expenses($M) | 125 | 128 | 117 | 122 | 122 | 114 | 118 | 137 | 134 | 145 | 118 | 134 | |
International Markets Segment — S&M Expenses (% of Segment Revenues)(%) | 21.2% | 23.3% | 22.3% | 23.0% | 21.9% | 23.0% | 20.2% | 20.7% | 21.9% | 24.5% | 19.8% | 21.9% | |
International Markets Segment — G&A Expenses($M) | 34 | 38 | 39 | 40 | 36 | 32 | 39 | 41 | 36 | 38 | 35 | 37 | |
International Markets Segment — G&A Expenses (% of Segment Revenues)(%) | 5.7% | 6.9% | 7.5% | 7.6% | 6.4% | 6.6% | 6.7% | 6.3% | 5.8% | 6.4% | 5.8% | 6.0% | |
International Markets Segment — Segment Profit Margin (% of Segment Revenues)(%) | 21.1% | 18.0% | 12.3% | 13.3% | 17.0% | 14.9% | 16.7% | 21.4% | 17.8% | 12.3% | 19.6% | 23.2% | |
International Markets Segment — Depreciation Expense($M) | 18 | 17 | 17 | 18 | 18 | 17 | |||||||
Legacy North America Segment — Total Revenues (FY2016–FY2023)($M)11 | 2,365 | ||||||||||||
Legacy North America Segment Revenues — Reported YoY Change(%) | 18.0% | ||||||||||||
Legacy North America Other Products — Reported YoY Change(%) | 347.0% | ||||||||||||
Legacy North America Segment — Gross Profit Margin (%)(%) | 62.2% | ||||||||||||
Legacy North America Segment — R&D Expenses($M) | 147 | ||||||||||||
Legacy North America Segment — R&D Expenses (% of Segment Revenues)(%) | 6.2% | ||||||||||||
Legacy North America Segment — S&M Expenses($M) | 262 | ||||||||||||
Legacy North America Segment — S&M Expenses (% of Segment Revenues)(%) | 11.0% | ||||||||||||
Legacy North America Segment — G&A Expenses($M) | 97 | ||||||||||||
Legacy North America Segment — G&A Expenses (% of Segment Revenues)(%) | 4.1% | ||||||||||||
Legacy North America Segment — Other Operating Income / (Expense)($M) | -2 | ||||||||||||
Legacy North America Segment — Segment Profit Margin (%)(%) | 40.9% | ||||||||||||
Total Reportable Segment Profit (U.S. + Europe + International Markets)($M)1 | 1,336 | 391 | 972 | 1,559 | 1,325 | 1,133 | 958 | 1,148 | 1,214 | 1,056 | 892 | 1,545 | |
Unallocated Amortization of Purchased Intangible Assets($M) | 139 | 139 | 137 | 145 | 144 | 148 | 145 | 144 | 146 | 146 | 152 | 144 | |
Other Activities — Total Revenues (Anda, Teva API, Medis & Contract Manufacturing)($M)2 | 613 | 627 | 584 | -904 | 598 | 597 | 579 | 241 | 229 | 249 | 225 | 245 | |
Other Activities Revenues — Reported YoY Change(%) | 3.0% | 5.0% | 1.0% | -6.0% | -10.0% | -7.0% | -9.0% | -2.0% | 6.0% | 2.0% | 3.0% | -10.0% | |
Other Activities Revenues — Local Currency YoY Change(%) | 3.0% | 5.0% | -1.0% | -9.0% | -13.0% | -9.0% | -8.0% | -2.0% | 5.0% | 2.0% | 2.0% | -11.0% | |
Anda, Inc. — Third-Party Pharmaceutical Distribution Revenues (U.S.)($M) | 401 | 413 | 378 | -1,130 | 392 | 365 | 373 | 402 | 380 | 373 | 381 | 394 | |
Teva API (TAPI) — Active Pharmaceutical Ingredient Sales to Third Parties($M)4 | 115 | 118 | 109 | 136 | 125 | 135 | 130 | 145 | 130 | 151 | 128 | ||
Teva API Third-Party Sales — Reported YoY Change(%) | -8.0% | -12.0% | -17.0% | -4.0% | -4.0% | -11.0% | 2.0% | 4.0% | 5.0% | 2.0% | |||
Teva API Third-Party Sales — Local Currency YoY Change(%) | -8.0% | -12.0% | -17.0% | -4.0% | -4.0% | -11.0% | 2.0% | 4.0% | 5.0% | 2.0% | |||
Teva API (TAPI) Reporting Unit — Goodwill Carrying Balance($M) | 0 | 0 | 0 | 0 | 0 | 318 | 895 | 1,299 | 1,313 | ||||
Teva API (TAPI) Disposal Group — Total Assets Held for Sale (Q1–Q3 2025)($M)9 | 1,836 | 1,794 | 1,794 | 1,842 | 1,809 | 1,842 | 1,814 | 1,771 | 2 | 69 | 70 | 70 | |
TAPI Disposal Group — Inventories Held for Sale($M) | 560 | 534 | 527 | 506 | 512 | 520 | 502 | 647 | 169 | 159 | 169 | 12 | |
TAPI Disposal Group — Property, Plant & Equipment Held for Sale($M) | 1,087 | 1,027 | 1,017 | 1,020 | 975 | 955 | 930 | 913 | 10 | 13 | 13 | 5 | |
TAPI Disposal Group — Trade Accounts Receivable Held for Sale($M) | 68 | 64 | 47 | 86 | 91 | 118 | 73 | 222 | 123 | 114 | 146 | 0 | |
TAPI Disposal Group — Goodwill Held for Sale($M) | 223 | 207 | 207 | 213 | 207 | 207 | 207 | 255 | 48 | 78 | 78 | 30 | |
TAPI Disposal Group — Intangible Assets Held for Sale($M) | 18 | 19 | 19 | 29 | 21 | 21 | 22 | 83 | 67 | 60 | 63 | 0 | |
TAPI Disposal Group — Other Current Assets Held for Sale($M) | 73 | 59 | 86 | 87 | 93 | 107 | 107 | 99 | 23 | ||||
TAPI Disposal Group — Other Non-Current Assets Held for Sale($M) | 180 | 184 | 174 | 184 | 190 | 198 | 201 | 236 | 0 | ||||
TAPI Disposal Group — Total Liabilities Held for Sale($M) | 296 | 313 | 334 | 354 | 324 | 334 | 358 | 698 | 216 | 356 | 262 | 13 | |
TAPI Disposal Group — Trade Accounts Payable Held for Sale($M) | 211 | 247 | 252 | 261 | 227 | 235 | 243 | 283 | 76 | 73 | 92 | 0 | |
Medis Out-Licensing & Contract Manufacturing — Additional Other Activities Revenues($M)1 | 98 | 95 | 97 | ||||||||||
Medis Reporting Unit — Goodwill Carrying Balance($M) | 292 | 291 | 291 | 256 | 232 | 269 | 251 | 255 | 265 | ||||
Sales Reserves and Allowances — Total Ending Balance (Liability)($M)8 | 3,955 | 3,899 | 3,707 | 4,143 | 4,134 | 4,050 | 3,696 | 3,678 | 3,785 | 3,700 | 3,594 | 3,535 | |
GTN Reserve Balance — Customer Volume & Prompt-Pay Rebates($M) | 1,865 | 1,800 | 1,657 | 1,954 | 2,011 | 1,849 | 1,682 | 1,674 | 1,787 | 1,738 | 1,628 | 1,603 | |
GTN Reserve Balance — Medicaid and Other U.S. Government Pricing Programs($M) | 717 | 675 | 685 | 701 | 662 | 626 | 601 | 561 | 592 | 568 | 567 | 540 | |
GTN Reserve Balance — Wholesaler Chargebacks($M) | 861 | 903 | 833 | 937 | 875 | 998 | 875 | 936 | 897 | 869 | 850 | 859 | |
GTN Reserve Balance — Product Returns($M) | 397 | 409 | 428 | 445 | 446 | 434 | 412 | 399 | 389 | 432 | 433 | 436 | |
GTN Reserve Balance — Promotional & Other Sales Allowances($M) | 115 | 112 | 104 | 106 | 140 | 143 | 126 | 108 | 120 | 93 | 116 | 97 | |
GTN Reserves Included in Accounts Receivable, Net($M) | 62 | 59 | 60 | 63 | 71 | 65 | 72 | 56 | 63 | 70 | 67 | 61 | |
Total Sales Reserves & Allowances (Including AR Reserves)($M) | 4,017 | 3,958 | 3,767 | 4,206 | 4,205 | 4,115 | 3,768 | 3,734 | 3,848 | 3,770 | 3,661 | 3,596 | |
Sales Reserves and Allowances — Balance Sheet Line Item($M) | 3,955 | 3,899 | 3,707 | 4,143 | 4,134 | 4,050 | 3,696 | 3,678 | 3,785 | 3,700 | 3,594 | 3,535 | |
GTN Provisions Charged to Revenue — Current-Period Sales (Total)($M)7 | 3,558 | 3,653 | 3,408 | 3,753 | 3,588 | 3,700 | 3,556 | 3,527 | 3,381 | 3,542 | 3,354 | 3,271 | |
GTN Provisions (Current-Year Sales) — Rebates($M) | 1,232 | 1,223 | 1,164 | 1,383 | 1,226 | 1,270 | 1,250 | 1,204 | 1,111 | 1,207 | 1,118 | 1,047 | |
GTN Provisions (Current-Year Sales) — Medicaid & Government Pricing($M) | 330 | 304 | 292 | 297 | 267 | 267 | 219 | 208 | 197 | 201 | 181 | 186 | |
GTN Provisions (Current-Year Sales) — Wholesaler Chargebacks($M) | 1,946 | 2,028 | 1,849 | 1,993 | 1,978 | 2,046 | 1,988 | 2,027 | 1,975 | 2,008 | 1,942 | 1,943 | |
GTN Provisions (Current-Year Sales) — Product Returns($M) | 73 | 65 | 65 | 76 | 70 | 74 | 69 | 85 | 45 | 73 | 73 | 59 | |
GTN Provisions (Current-Year Sales) — Promotional & Other Allowances($M) | -23 | 33 | 38 | 4 | 47 | 43 | 30 | 3 | 65 | 41 | 40 | 36 | |
GTN Provisions (Current-Year Sales) — Reserves Included in AR($M) | 101 | 98 | 88 | 102 | 107 | 104 | 99 | 96 | 100 | 101 | 93 | 92 | |
GTN Provisions (Current-Year Sales) — Grand Total (Incl. AR Reserves)($M) | 3,659 | 3,751 | 3,496 | 3,855 | 3,695 | 3,804 | 3,655 | 3,623 | 3,487 | 3,637 | 3,447 | 3,363 | |
GTN Provisions Charged / (Credited) to Revenue — Prior-Year Sales Adjustments($M)7 | -14 | -69 | -59 | -10 | 4 | 3 | -55 | -10 | -8 | -3 | 12 | -49 | |
GTN Prior-Year Adjustments — Rebates($M) | -31 | -18 | -29 | -8 | 8 | -9 | -37 | -11 | 4 | 2 | 10 | -9 | |
GTN Prior-Year Adjustments — Medicaid & Government Pricing($M) | 22 | -46 | -8 | 11 | 3 | 21 | 9 | -4 | 0 | 6 | 20 | 0 | |
GTN Prior-Year Adjustments — Wholesaler Chargebacks($M) | 4 | 1 | -11 | 0 | -1 | -8 | -20 | 0 | 0 | 0 | -11 | -33 | |
GTN Prior-Year Adjustments — Product Returns($M) | -11 | -4 | -8 | -12 | -2 | 2 | -3 | 6 | -11 | -11 | -6 | -7 | |
GTN Prior-Year Adjustments — Other Allowances($M) | 2 | -2 | -3 | -1 | -4 | -3 | -4 | -1 | -1 | 0 | -1 | 0 | |
GTN Prior-Year Adjustments — Reserves Included in AR($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
GTN Prior-Year Adjustments — Grand Total (Incl. AR Reserves)($M) | -14 | -69 | -59 | -10 | 4 | 3 | -55 | -10 | -8 | -3 | 12 | -49 | |
GTN Credits, Payments & Deductions Applied Against Reserves (Total)($M)8 | 3,476 | 3,387 | 3,763 | 3,742 | 3,503 | 3,430 | 3,523 | 3,543 | 3,327 | 3,428 | 3,277 | 3,087 | |
GTN Credits & Payments Applied — Rebates($M) | 1,131 | 1,056 | 1,419 | 1,437 | 1,069 | 1,139 | 1,224 | 1,262 | 1,086 | 1,097 | 1,086 | 985 | |
GTN Credits & Payments Applied — Medicaid & Government Pricing($M) | 308 | 269 | 297 | 269 | 233 | 275 | 193 | 225 | 180 | 205 | 171 | 131 | |
GTN Credits & Payments Applied — Wholesaler Chargebacks($M) | 1,991 | 1,958 | 1,939 | 1,933 | 2,100 | 1,927 | 2,035 | 1,974 | 1,954 | 1,988 | 1,935 | 1,894 | |
GTN Credits & Payments Applied — Product Returns($M) | 73 | 80 | 73 | 65 | 56 | 57 | 55 | 77 | 80 | 62 | 67 | 53 | |
GTN Credits & Payments Applied — Other Allowances($M) | -27 | 24 | 35 | 38 | 45 | 32 | 16 | 5 | 39 | 64 | 18 | 24 | |
GTN Credits & Payments Applied — Reserves Included in AR($M) | 98 | 99 | 91 | 110 | 101 | 111 | 83 | 103 | 108 | 97 | 87 | 92 | |
GTN Credits & Payments Applied — Grand Total (Incl. AR Reserves)($M) | 3,574 | 3,486 | 3,854 | 3,852 | 3,604 | 3,541 | 3,606 | 3,646 | 3,440 | 3,520 | 3,364 | 3,179 | |
GTN Reserves — Foreign Currency Translation & Other Adjustments($M) | -12 | -5 | -22 | 8 | -5 | 81 | 40 | -81 | 39 | -5 | -30 | 49 | |
Accounts Receivable Securitization — Cash Proceeds / Beneficial Interest Collected($M)2 | 327 | 311 | 354 | 282 | 274 | 336 | 322 | 340 | 339 | 317 | 295 | 421 | |
Supplier Finance Program Obligations Outstanding (Confirmed Payment Obligations)($M) | 242 | 257 | 251 | 225 | 171 | 196 | 189 | 158 | 163 | 131 | 99 | 108 | |
Allowance for Credit Losses on Trade Accounts Receivable($M) | 71 | 75 | 75 | 81 | 82 | 84 | 80 | 78 | 91 | 95 | 98 | 95 | |
Adjusted EBITDA (Non-GAAP)($M)12 | 1,496 | 474 | 1,055 | 1,637 | 1,394 | 1,233 | 1,041 | 1,282 | 1,327 | 1,168 | 1,005 | 1,660 | |
EBITDA (GAAP Operating Income + Depreciation & Amortization)($M) | 959 | 10 | 892 | 560 | 1,131 | 705 | 763 | 235 | 208 | 254 | 54 | 1,020 | |
Non-GAAP Gross Profit($M) | 2,580 | 2,293 | 2,108 | 9,647 | 2,475 | 2,278 | 2,054 | 2,319 | 2,327 | 2,205 | 1,963 | 8,470 | |
Non-GAAP Gross Profit Margin (%)(%) | 58.7% | 55.4% | 52.9% | 60.3% | 55.3% | 54.6% | 52.8% | 54.8% | 53.7% | 52.9% | 51.4% | 58.2% | |
GAAP Gross Profit (Per Non-GAAP Reconciliation Table)($M) | 2,440 | 2,153 | 1,972 | 2,304 | 2,102 | 1,877 | 2,148 | 2,024 | 1,771 | ||||
GAAP Gross Profit Margin (%)(%) | 55.5% | 52.0% | 49.5% | 51.4% | 50.3% | 48.2% | 49.6% | 48.6% | 46.4% | ||||
Non-GAAP Operating Income($M) | 1,393 | 375 | 956 | 4,905 | 1,294 | 375 | 946 | 4,329 | 1,214 | 1,056 | 892 | 4,361 | |
GAAP Operating Income / (Loss) Margin (%)(%) | 16.2% | -5.6% | 16.4% | 6.4% | 19.7% | 10.9% | 13.3% | 0.7% | -1.2% | -0.1% | -5.7% | ||
Non-GAAP Net Income Attributable to Teva($M) | 1,013 | 21 | 621 | 3,411 | 910 | 769 | 602 | 2,860 | 798 | 697 | -139 | 2,812 | |
Non-GAAP Diluted Weighted Average Shares(M) | 1,183 | 1,181 | 1,179 | 1,173 | 1,164 | 1,161 | 1,159 | 1,157 | 1,155 | 1,151 | 1,143 | 1,137 | |
Non-GAAP Effective Tax Rate (%)(%) | 16.5% | 86.7% | 17.5% | 15.5% | 14.7% | 16.4% | 17.5% | 14.8% | 16.0% | 15.4% | 15.0% | 13.1% | |
Depreciation Expense (Per EBITDA Reconciliation)($M) | 106 | 102 | 102 | 114 | 105 | 103 | 99 | 119 | 113 | 113 | 119 | 120 | |
Amortization of Purchased Intangible Assets (Per Non-GAAP Reconciliation)($M) | 139 | 139 | 137 | 145 | 144 | 148 | 145 | 144 | 146 | 146 | 152 | 144 | |
Free Cash Flow (Teva Non-GAAP Definition)($M)4 | 495 | 622 | 188 | 1,298 | 515 | 476 | 107 | 790 | 922 | 324 | 32 | 1,486 | |
Net Cash Provided by / (Used in) Operating Activities (Per FCF Table)($M) | 241 | 411 | -40 | 1,158 | 369 | 227 | -105 | 575 | 693 | 103 | -124 | 1,184 | |
Beneficial Interest Collected in Exchange for Securitized Trade Receivables($M) | 327 | 311 | 354 | 282 | 274 | 336 | 322 | 340 | 339 | 317 | 295 | 421 | |
Cash Used for Capital Investments (Per FCF Table)($M) | -120 | -104 | -168 | -142 | -136 | -96 | -127 | -129 | -148 | -97 | -124 | -120 | |
Proceeds from Sale of Businesses and Long-Lived Assets($M) | 47 | 4 | 42 | 0 | 8 | 9 | 17 | 4 | 38 | 1 | 0 | 0 | |
Net Debt (Total Debt Less Cash & Cash Equivalents)($M)8 | 12,633 | 12,938 | 12,886 | ||||||||||
Total Debt (Per Net Debt Reconciliation)($M) | 16,718 | 16,593 | 16,627 | 16,807 | |||||||||
Senior Notes and Loans (Total Carrying Value)($M) | 16,786 | 16,650 | 16,677 | 16,850 | 16,836 | 17,259 | 16,687 | 17,821 | 19,023 | 18,686 | 19,695 | 19,889 | |
Short-Term Debt & Current Maturities($M) | 4,038 | 4,500 | 2,612 | 1,820 | 24 | 464 | 421 | 1,781 | 2,580 | 2,094 | 3,060 | 1,672 | |
Cash and Cash Equivalents($M) | 4,085 | 3,655 | 3,741 | 3,556 | 2,203 | 2,161 | 1,697 | 3,300 | 3,319 | 2,258 | 2,991 | 3,226 | |
Total Long-Term Debt — Estimated Fair Value($M) | 16,185 | 16,586 | 16,458 | 16,929 | 16,831 | 17,133 | 16,357 | 17,496 | 18,701 | 17,893 | 18,837 | 18,865 | |
Financial Leverage Ratio (Debt to Total Debt + Equity)(%) | 68.0% | 68.0% | 67.0% | 68.0% | 77.0% | 72.0% | 71.0% | ||||||
Short-Term Debt Share of Total Debt (%)(%) | 24.0% | 27.0% | 16.0% | 11.0% | 3.0% | 3.0% | 14.0% | 11.0% | |||||
Share of Total Debt Denominated in U.S. Dollars (%)(%) | 60.0% | 57.0% | 57.0% | 57.0% | 57.0% | 55.0% | 63.0% | 61.0% | 58.0% | 59.0% | 60.0% | 60.0% | |
Legal Settlements and Loss Contingencies — Total Provision Balance($M)1 | 4,720 | 4,854 | 4,680 | 4,753 | 4,668 | 5,002 | 4,877 | 4,881 | 4,915 | 4,730 | 4,669 | 4,771 | |
Legal Settlements and Loss Contingencies Expense / (Benefit)($M) | 202 | 230 | 72 | 155 | 60 | 166 | 86 | 123 | 450 | 83 | 106 | 34 | |
Restructuring Liability Reserve — Ending Balance (Total)($M)8 | 114 | 111 | 118 | 138 | 168 | 182 | 57 | 68 | 70 | 55 | 57 | 82 | |
Restructuring Reserve — Employee Termination Costs($M) | 101 | 97 | 104 | 124 | 154 | 168 | 44 | 55 | 56 | 49 | 50 | 75 | |
Restructuring Reserve — Other Restructuring Costs($M) | 13 | 14 | 14 | 14 | 14 | 14 | 13 | 13 | 14 | 6 | 6 | 7 | |
Restructuring Expense Recognized in Operations — Total($M) | 58 | 38 | 25 | 29 | 29 | 154 | 14 | 22 | 21 | 18 | 13 | 18 | |
Restructuring Expense — Employee Termination($M) | 57 | 37 | 22 | 24 | 28 | 151 | 12 | 20 | 13 | 13 | 7 | 12 | |
Restructuring Expense — Other Costs($M) | 1 | 1 | 3 | 5 | 1 | 3 | 2 | 2 | 8 | 5 | 6 | 6 | |
Restructuring Reserve — Cash Payments & Utilization (Total)($M) | 55 | 45 | 45 | 60 | 42 | 29 | 25 | 24 | 6 | 19 | 39 | 19 | |
Restructuring Reserve Utilization — Employee Termination($M) | 53 | 44 | 42 | 55 | 42 | 27 | 23 | 21 | 6 | 14 | 32 | 13 | |
Restructuring Reserve Utilization — Other Costs($M) | 2 | 1 | 3 | 5 | 0 | 2 | 2 | 4 | 0 | 5 | 7 | 6 | |
Operating Lease Liabilities — Total Balance2 | |||||||||||||
Operating Lease Right-of-Use (ROU) Assets($M) | 321 | 333 | 335 | 345 | 342 | 358 | 363 | 367 | 364 | 358 | 364 | 397 | |
Operating Lease Liabilities — Non-Current($M) | 266 | 282 | 280 | 288 | 283 | 296 | 288 | 296 | 295 | 281 | 294 | 320 | |
Property, Plant and Equipment, Net — Entity-Wide Geographic Breakdown($M) | 3,747 | 3,928 | 3,998 | 4,080 | 4,820 | 4,810 | 4,631 | 4,581 | 5,672 | 5,573 | 5,618 | 5,750 | |
U.S. Real Personal Consumption Expenditures — Pharmaceutical and Other Medical Products (SAAR) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
GAAP Consolidated Revenues($M)20 | 4,395 | 4,142 | 3,982 | 1,500 | 4,480 | 4,176 | 3,891 | 4,229 | 4,332 | 4,164 | 3,819 | 4,457 | |
GAAP Cost of Sales($M) | 1,955 | 1,989 | 2,011 | 2,056 | 2,176 | 2,074 | 2,014 | 2,109 | 2,183 | 2,140 | 2,048 | 2,041 | |
GAAP Gross Profit($M) | 2,440 | 2,153 | 1,972 | 2,656 | 2,304 | 2,102 | 1,877 | 2,121 | 2,148 | 2,024 | 1,771 | 2,415 | |
GAAP Research and Development (R&D) Expenses, Net($M) | 297 | 970 | 222 | 267 | 256 | 244 | 247 | 247 | 240 | 269 | 242 | 227 | |
GAAP Selling and Marketing (S&M) Expenses($M) | 709 | 717 | 696 | 753 | 656 | 654 | 622 | 650 | 626 | 656 | 608 | 610 | |
GAAP General and Administrative (G&A) Expenses($M) | 298 | 317 | 304 | 367 | 317 | 305 | 297 | 302 | 298 | 283 | 278 | 292 | |
GAAP Amortization of Purchased Intangible Assets($M) | 139 | 139 | 137 | 145 | 144 | 148 | 145 | 144 | 146 | 146 | 152 | 145 | |
GAAP Impairment of Long-Lived Intangible Assets($M) | 24 | 22 | 8 | 32 | 64 | 42 | 121 | 82 | 28 | 61 | 80 | 61 | |
GAAP Impairment of Long-Lived Tangible Assets($M) | 204 | 91 | 1 | 741 | 15 | 58 | 44 | 435 | 80 | 69 | 599 | 7 | |
GAAP Other Asset Impairments, Restructuring and Other Items($M) | 264 | 147 | 26 | 778 | 62 | 232 | -22 | 457 | -23 | 280 | 673 | 442 | |
GAAP Operating Income / (Loss)($M) | 714 | -231 | 652 | 300 | 882 | 455 | 519 | -29 | -51 | -5 | -218 | 756 | |
GAAP Financial Expenses, Net($M) | -414 | -224 | -216 | -220 | -237 | -252 | -225 | -218 | -272 | -241 | -250 | -249 | |
GAAP Income / (Loss) Before Income Taxes($M) | 300 | -455 | 437 | 80 | 646 | 203 | 294 | -247 | -324 | -246 | -467 | 507 | |
GAAP Income Tax Expense / (Benefit)($M) | 66 | 121 | 67 | -390 | 214 | -78 | 74 | 28 | 69 | 630 | -52 | 41 | |
GAAP Consolidated Net Income / (Loss) Before Attribution($M) | 234 | -575 | 369 | 481 | 434 | 283 | 220 | -275 | -390 | -874 | -419 | 467 | |
GAAP Net Income / (Loss) Attributable to Teva($M) | 233 | -576 | 369 | 480 | 433 | 282 | 214 | -217 | -437 | -846 | -139 | 463 | |
GAAP Basic EPS Attributable to Teva | 0.20 | -0.49 | 0.32 | 0.38 | 0.25 | 0.19 | -0.39 | -0.75 | -0.12 | ||||
GAAP Diluted EPS Attributable to Teva | 0.20 | -0.49 | 0.31 | 0.37 | 0.24 | 0.18 | -0.39 | -0.75 | -0.12 | ||||
GAAP Basic Weighted Average Shares(M) | 1,166 | 1,165 | 1,156 | 1,147 | 1,147 | 1,138 | 1,133 | 1,133 | 1,123 | ||||
GAAP Diluted Weighted Average Shares(M) | 1,183 | 1,165 | 1,179 | 1,164 | 1,161 | 1,159 | 1,133 | 1,133 | 1,123 | ||||
Potentially Dilutive Securities Excluded from Diluted EPS (Anti-Dilutive)(M) | 17 | 0 | 23 | 17 | 14 | 21 | |||||||
GAAP Total Assets($M)11 | 40,042 | 39,857 | 40,040 | 40,748 | 39,856 | 40,131 | 38,415 | 39,326 | 41,758 | 41,338 | 42,773 | 43,479 | |
GAAP Total Current Assets($M) | 14,602 | 13,760 | 13,710 | 13,946 | 12,736 | 12,620 | 11,528 | 12,552 | 12,314 | 11,632 | 12,297 | 12,485 | |
GAAP Cash and Cash Equivalents($M) | 4,085 | 3,655 | 3,741 | 3,556 | 2,203 | 2,161 | 1,697 | 3,300 | 3,319 | 2,258 | 2,991 | 3,226 | |
GAAP Trade Accounts Receivable, Net($M) | 3,837 | 3,493 | 3,393 | 3,709 | 3,810 | 3,564 | 3,384 | 3,059 | 3,462 | 3,766 | 3,456 | 3,408 | |
GAAP Inventories, Net (Total)($M)4 | 3,173 | 3,221 | 3,176 | 3,179 | 3,323 | 3,497 | 3,247 | 3,007 | 3,959 | 3,927 | 3,949 | 4,021 | |
Inventories — Raw Materials($M) | 705 | 751 | 730 | 745 | 799 | 724 | 716 | 671 | 926 | 982 | 1,014 | 993 | |
Inventories — Work in Process($M) | 431 | 423 | 386 | 364 | 330 | 392 | 377 | 353 | 524 | 489 | 508 | 500 | |
Inventories — Finished Goods($M) | 1,875 | 1,843 | 1,848 | 1,904 | 2,027 | 2,106 | 1,895 | 1,783 | 2,314 | 2,269 | 2,238 | 2,346 | |
Inventories — Materials in Transit and Payments on Account($M) | 163 | 204 | 213 | 166 | 168 | 276 | 259 | 199 | 195 | 186 | 189 | 183 | |
GAAP Prepaid Expenses($M) | 1,014 | 1,034 | 1,070 | 1,122 | 1,115 | 1,084 | 1,018 | 1,006 | 1,127 | 1,096 | 1,336 | 1,255 | |
GAAP Other Current Assets($M) | 658 | 563 | 535 | 539 | 477 | 472 | 368 | 409 | 445 | 517 | 495 | 504 | |
GAAP Property, Plant and Equipment, Net($M) | 3,747 | 3,928 | 3,998 | 4,080 | 4,820 | 4,810 | 4,631 | 4,581 | 5,672 | 5,573 | 5,618 | 5,750 | |
GAAP Identifiable Intangible Assets, Net (Total)($M)9 | 3,303 | 3,447 | 3,609 | 3,781 | 3,936 | 4,142 | 4,189 | 4,418 | 4,756 | 4,853 | 5,056 | 5,387 | |
Intangible Assets, Net — Product Rights and Licenses($M) | 2,886 | 3,020 | 3,164 | 3,318 | 3,466 | 3,656 | 3,708 | 3,917 | 4,173 | 4,234 | 4,415 | 4,707 | |
Intangible Assets, Net — Trade Names($M) | 225 | 235 | 244 | 257 | 264 | 273 | 269 | 268 | 290 | 290 | 300 | 314 | |
Intangible Assets, Net — In-Process Research and Development (IPR&D)($M) | 192 | 192 | 201 | 206 | 206 | 213 | 212 | 233 | 294 | 329 | 341 | 366 | |
Intangible Assets — Gross Carrying Amount (Total)($M) | 16,859 | 16,923 | 16,966 | 17,111 | 17,139 | 17,207 | 16,764 | 16,716 | 17,287 | 17,090 | 17,178 | 18,930 | |
Intangible Assets Gross — Product Rights and Licenses($M) | 16,078 | 16,140 | 16,174 | 16,308 | 16,338 | 16,399 | 15,973 | 15,915 | 16,408 | 16,186 | 16,261 | 17,981 | |
Intangible Assets Gross — Trade Names($M) | 589 | 591 | 591 | 597 | 595 | 595 | 579 | 568 | 586 | 575 | 576 | 583 | |
Intangible Assets — Accumulated Amortization (Total)($M) | 13,556 | 13,476 | 13,357 | 13,330 | 13,203 | 13,065 | 12,575 | 12,298 | 12,531 | 12,237 | 12,122 | 13,543 | |
Intangible Assets Accumulated Amortization — Product Rights($M) | 13,192 | 13,120 | 13,010 | 12,990 | 12,872 | 12,743 | 12,265 | 11,998 | 12,235 | 11,952 | 11,846 | 13,274 | |
Intangible Assets Accumulated Amortization — Trade Names($M) | 364 | 356 | 347 | 340 | 331 | 322 | 310 | 300 | 296 | 285 | 276 | 269 | |
GAAP Goodwill (Total Carrying Value)($M)6 | 15,742 | 15,839 | 15,822 | 16,000 | 15,945 | 15,949 | 15,477 | 16,000 | 16,124 | 16,488 | 17,007 | 17,177 | |
Goodwill — United States Segment($M) | 5,542 | 5,548 | 5,548 | 5,548 | 5,732 | 5,732 | 5,732 | 5,732 | 5,813 | 5,813 | 5,813 | 5,813 | |
Goodwill — Europe Segment($M) | 8,573 | 8,628 | 8,645 | 8,812 | 8,795 | 8,806 | 8,316 | 8,812 | 8,563 | 8,323 | 8,362 | 8,466 | |
Goodwill — International Markets Segment($M) | 1,169 | 1,202 | 1,165 | 1,166 | 1,128 | 1,122 | 1,174 | 1,166 | 1,161 | 1,208 | 1,279 | 1,321 | |
Goodwill — Other Activities (TAPI & Medis)($M) | 460 | 463 | 465 | 476 | 292 | ||||||||
Goodwill — Legacy North America Segment (FY2016–FY2024)($M) | 0 | 0 | 0 | 0 | 6,459 | ||||||||
Goodwill — Accumulated Impairment Losses($M) | 29,600 | 29,600 | 29,600 | 29,600 | 29,600 | 29,600 | 29,600 | 29,600 | 29,300 | 28,700 | 28,300 | 28,300 | |
GAAP Deferred Income Taxes (Non-Current Asset)($M) | 2,057 | 2,162 | 2,190 | 2,191 | 1,634 | 1,781 | 1,762 | 1,799 | 2,070 | 2,000 | 1,960 | 1,812 | |
GAAP Other Non-Current Assets($M) | 269 | 387 | 377 | 405 | 444 | 470 | 464 | 462 | 459 | 434 | 470 | 470 | |
GAAP Total Liabilities($M)13 | 32,057 | 32,100 | 31,809 | 32,834 | 32,602 | 33,297 | 32,146 | 33,606 | 35,375 | 34,774 | 35,230 | 35,353 | |
GAAP Total Current Liabilities($M) | 15,425 | 15,646 | 13,532 | 13,456 | 11,491 | 11,861 | 11,157 | 12,796 | 13,797 | 13,037 | 13,792 | 12,247 | |
GAAP Short-Term Debt (Total)($M) | 4,038 | 4,500 | 2,612 | 1,820 | 24 | 464 | 421 | 1,781 | 2,580 | 2,094 | 3,060 | 1,672 | |
Short-Term Debt — Current Maturities & Bank Borrowings($M) | 0 | 0 | 0 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | |
Short-Term Debt — Current Maturities of Senior Notes($M) | 4,038 | 4,500 | 2,600 | 1,798 | 0 | 438 | 1,758 | ||||||
Short-Term Debt — Current Maturities of Long-Term Loans($M) | 4,038 | 4,500 | 2,600 | 1,798 | 1 | 441 | 398 | 1,758 | 2,557 | 2,071 | 3,037 | 1,649 | |
GAAP Trade Accounts Payable($M) | 2,551 | 2,721 | 2,596 | 2,531 | 2,355 | 2,498 | 2,290 | 2,203 | 2,371 | 2,366 | 2,439 | 2,602 | |
GAAP Employee-Related Obligations (Current)($M) | 588 | 488 | 555 | 739 | 561 | 481 | 474 | 624 | 619 | 492 | 492 | 611 | |
GAAP Accrued Expenses (Current)($M) | 2,962 | 2,738 | 2,616 | 2,687 | 2,989 | 3,095 | 2,952 | 2,792 | 2,984 | 2,840 | 2,784 | 2,771 | |
GAAP Other Current Liabilities($M) | 1,036 | 987 | 1,111 | 1,182 | 1,103 | 940 | 964 | 1,020 | 1,241 | 1,191 | 1,161 | 1,044 | |
GAAP Total Non-Current Liabilities($M) | 16,632 | 16,454 | 18,277 | 19,379 | 21,111 | 21,436 | 20,990 | 20,809 | 21,578 | 21,737 | 21,438 | 23,106 | |
GAAP Long-Term Debt — Senior Notes and Loans (Non-Current)($M) | 12,680 | 12,092 | 14,015 | 14,986 | 16,766 | 16,763 | 16,230 | 16,002 | 16,400 | 16,547 | 16,584 | 18,161 | |
GAAP Deferred Income Taxes (Non-Current Liability)($M) | 263 | 289 | 273 | 296 | 399 | 440 | 461 | 483 | 538 | 553 | 569 | 606 | |
GAAP Other Taxes and Long-Term Liabilities($M) | 3,422 | 3,791 | 3,709 | 3,808 | 3,664 | 3,938 | 4,011 | 4,028 | 4,344 | 4,356 | 3,991 | 4,019 | |
GAAP Total Equity (Including Non-Controlling Interests)($M)10 | 7,984 | 7,757 | 8,232 | 7,914 | 7,254 | 6,834 | 6,269 | 5,380 | 6,383 | 6,563 | 7,543 | 8,126 | |
GAAP Teva Shareholders' Equity($M) | 7,979 | 7,753 | 8,228 | 7,910 | 7,250 | 6,827 | 6,262 | 5,373 | 6,065 | 6,359 | 7,278 | 7,506 | |
GAAP Ordinary Shares Carrying Value($M) | 59 | 59 | 59 | 58 | 58 | 58 | 58 | 58 | 58 | 58 | 58 | 57 | |
GAAP Additional Paid-In Capital($M) | 28,309 | 28,256 | 28,203 | 28,133 | 28,038 | 28,003 | 27,965 | 27,764 | 27,860 | 27,829 | 27,796 | 27,807 | |
GAAP Retained Earnings / (Accumulated Deficit)($M) | -13,736 | -13,969 | -13,394 | -13,762 | -14,243 | -14,676 | -14,958 | -15,173 | -14,956 | -14,519 | -13,673 | -13,534 | |
GAAP Accumulated Other Comprehensive Income / (Loss)($M) | -2,556 | -2,465 | -2,512 | -2,391 | -2,475 | -2,431 | -2,675 | -3,148 | -2,769 | -2,881 | -2,775 | -2,697 | |
GAAP Treasury Shares Held at Cost($M) | 4,097 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 | |
GAAP Non-Controlling Interests($M) | 5 | 4 | 4 | 4 | 4 | 7 | 7 | 7 | 319 | 204 | 265 | 620 | |
Ordinary Shares Issued at Period-End(M) | 1,300 | 1,271 | 1,271 | 1,300 | 1,253 | 1,253 | 1,253 | 1,240 | 1,240 | 1,239 | 1,238 | 1,227 | |
Ordinary Shares Outstanding at Period-End(M) | 1,167 | 1,165 | 1,164 | 1,150 | 1,147 | 1,147 | 1,147 | 1,134 | 1,133 | 1,133 | 1,133 | 1,121 | |
Treasury Shares Held at Period-End(M) | 105 | 106 | 107 | 107 | 106 | 106 | 106 | 107 | 106 | 106 | 106 | 106 | |
GAAP Net Cash Provided by / (Used in) Operating Activities($M)9 | 241 | 411 | -40 | 1,158 | 369 | 227 | -105 | 575 | 693 | 103 | -124 | 1,184 | |
GAAP Share-Based Compensation Expense($M) | 38 | 40 | 43 | 51 | 34 | 38 | 34 | 34 | 29 | 32 | 28 | 28 | |
GAAP Net Gain / (Loss) on Sale of Long-Lived Assets & Divestitures($M) | 69 | 12 | 8 | 0 | 0 | 2 | -2 | 0 | 21 | 1 | 0 | 12 | |
GAAP Net Cash Provided by / (Used in) Investing Activities($M) | 210 | -491 | 229 | 165 | 135 | 236 | 201 | 202 | 268 | 178 | 144 | 301 | |
GAAP Purchases of Property, Plant and Equipment (Capital Expenditures)($M) | -120 | -104 | -168 | -142 | -136 | -96 | -127 | -129 | -148 | -97 | -124 | -119 | |
GAAP Net Cash Provided by / (Used in) Financing Activities($M) | 6 | -1 | 13 | 40 | -453 | 6 | -1,744 | -674 | 0 | -966 | -151 | -576 | |
Proceeds from Exercise of Options and Employee Share Plans($M) | 46 | 13 | 26 | 44 | 0 | 0 | 3 | 12 | 1 | 0 | 6 | ||
Effect of Exchange Rate Changes on Cash and Cash Equivalents($M) | -27 | -5 | -17 | -10 | -9 | -5 | 45 | -121 | 100 | -49 | -104 | 68 | |
Net Change in Cash, Cash Equivalents and Restricted Cash($M) | 430 | -86 | 185 | 1,353 | 42 | 464 | -1,603 | -18 | 1,061 | -733 | -236 | 977 | |
Cash, Cash Equivalents and Restricted Cash at Period-End($M) | 4,085 | 3,655 | 3,741 | 3,556 | 2,203 | 2,161 | 1,697 | 3,300 | 3,319 | 2,258 | 2,991 | 3,227 | |
55 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Segment Realignment (Q1 2026): Beginning in Q1 2026, Teva realigned its former North America segment to establish a standalone United States reportable segment. Canada was moved to the International Markets segment and Anda, Inc. (Teva's U.S. distribution business) was moved to Other Activities. Comparative segment and product figures for FY2022–FY2025 and Q1 2023–Q4 2025 have been retrospectively restated; historical FY2016–FY2023 North America figures are preserved on dedicated Legacy North America rows.
- Period-Split Derivations: Quarterly cash flow items and Gross-to-Net (GTN) sales reserve rollforward flows reported on a cumulative 6-month (Q2), 9-month (Q3), or full-year (10-K) basis are split into standalone quarters via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = FY − Q1 − Q2 − Q3 (or FY − 9M), marked with their exact derivation formula.
- Currency & Units: Monetary figures are expressed in millions of U.S. dollars ($M) unless otherwise indicated ($B for branded market value of pending ANDAs and healthcare system savings; $/sh for per-share figures; actual dollars for compensation). Local-currency (LC) growth rates are presented as published by Teva in constant exchange rates.
Không hiện vì thiếu các kỳ gần đây (13)
- Non-GAAP Operating Income Margin (%) — Discontinued or sparse quarterly disclosure (last reported in FY2026Q3; fewer than 3 consecutive quarters through FY2026Q3)
- Syndicated Sustainability-Linked Revolving Credit Facility Capacity — Discontinued or sparse quarterly disclosure (last reported in FY2026Q3; fewer than 3 consecutive quarters through FY2026Q3)
- Energy Intensity (kWh per USD of Revenue) — Discontinued annual disclosure (last reported in FY2022; missing FY2025 or prior year)
- Revenue — Legacy Specialty Medicines Segment (Discontinued after FY2017 restructuring into regional segments; lacks continuity to FY2026Q3)
- Revenue — Legacy Generic Medicines Segment (Discontinued after FY2017 restructuring into regional segments; lacks continuity to FY2026Q3)
- Treanda / Bendeka International Markets Revenue (Discontinued separate disclosure after FY2024; lacks FY2025–FY2026Q3 continuity)
- Europe Distribution Revenue (Separately reported only in FY2018; merged into Other Products thereafter)
- International Markets Distribution Revenue (Separately reported only through FY2019; merged into Other Products thereafter)
- Goodwill Currency Translation Adjustments by Segment (Quarterly rollforward table only reported in select periods; not continuous across all quarters)
- Nationwide Opioid Settlement 5-Year Undiscounted Payment Schedule (Reported only in select 10-K/10-Q footnotes through Q2 2024)
- 5-Year Contractual Debt Maturity Schedule (Reported only in annual 10-K footnotes through FY2024; omitted in FY2025 10-K XBRL)
- Conflict Minerals (Form SD) — 3TG Suppliers Surveyed (Reported only in FY2022 and FY2025 Form SD filings; not continuous across FY2024–FY2025)
- Consolidated Minus Parent-Only Subsidiary Extraction (Excluded: Teva files consolidated U.S. GAAP financial statements on Form 10-K/10-Q without parent-only standalone financial statements; Rule 5-04 Schedule I condensed parent information is omitted as restricted net assets do not exceed 25% of consolidated net assets)
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Portfolio — Innovative Brands, Generic Rx Share & Medicine Revenues
- Consolidated Net Revenues ($M)43 kỳ
- AUSTEDO (deutetrabenazine) — Global Revenues ($M)3 kỳ
- AJOVY (fremanezumab) — Global Revenues ($M)3 kỳ
- UZEDY (risperidone LAI) — United States Segment Revenues ($M)13 kỳ
- U.S. Generic Prescriptions Dispensed — Trailing Twelve Months (IQVIA) (M)23 kỳ
- Generic Products (incl. Biosimilars & OTC) — United States Segment Revenues ($M)15 kỳ
- Generic Products (incl. OTC & Biosimilars) — Europe Segment Revenues ($M)39 kỳ
- Generic Products (incl. OTC & Biosimilars) — International Markets Segment Revenues ($M)39 kỳ
- COPAXONE (glatiramer acetate) — United States Segment Revenues ($M)15 kỳ
- BENDEKA and TREANDA (bendamustine) — United States Segment Revenues ($M)15 kỳ
- Respiratory Products — Europe Segment Revenues ($M)39 kỳ
R&D Pipeline, FDA ANDAs, European Regulatory Approvals & Contingent Milestones
Regional Segment Operating P&L, Expense Ratios & Revenue by Nature
Operating Subsidiaries & Other Activities — Anda Distribution, Teva API (TAPI) & Medis
- Other Activities — Total Revenues (Anda, Teva API, Medis & Contract Manufacturing) ($M)38 kỳ
- Anda, Inc. — Third-Party Pharmaceutical Distribution Revenues (U.S.) ($M)34 kỳ
- Teva API (TAPI) — Active Pharmaceutical Ingredient Sales to Third Parties ($M)32 kỳ
- Medis Out-Licensing & Contract Manufacturing — Additional Other Activities Revenues ($M)3 kỳ
Gross-to-Net (GTN) Sales Reserves Rollforward, Wholesaler Concentration & AR Securitization
- Sales Reserves and Allowances — Total Ending Balance (Liability) ($M)35 kỳ
- GTN Provisions Charged to Revenue — Current-Period Sales (Total) ($M)33 kỳ
- GTN Provisions Charged / (Credited) to Revenue — Prior-Year Sales Adjustments ($M)33 kỳ
- GTN Credits, Payments & Deductions Applied Against Reserves (Total) ($M)33 kỳ
- Share of U.S. Sales Reserves Attributable to Top 3 Pharmaceutical Wholesalers (%)7 kỳ
- Accounts Receivable Securitization — Cash Proceeds / Beneficial Interest Collected ($M)35 kỳ
Non-GAAP Earnings Reconciliations, Free Cash Flow, Net Debt & Legal/Restructuring Reserves
- Adjusted EBITDA (Non-GAAP) ($M)20 kỳ
- Free Cash Flow (Teva Non-GAAP Definition) ($M)35 kỳ
- Net Debt (Total Debt Less Cash & Cash Equivalents) ($M)3 kỳ
- Legal Settlements and Loss Contingencies — Total Provision Balance ($M)36 kỳ
- Restructuring Liability Reserve — Ending Balance (Total) ($M)37 kỳ
- Operating Lease Liabilities — Total Balance ($M)7 kỳ
- Unrecognized Tax Benefits (UTB) — Ending Liability Balance ($M)11 kỳ
Manufacturing & R&D Footprint, Global Workforce, Governance & Sustainability (ESG)
- Manufacturing & R&D Facilities — Worldwide Total9 kỳ
- Property, Plant and Equipment, Net — Entity-Wide Geographic Breakdown ($M)43 kỳ
- Total Workforce Full-Time Equivalent (FTE)10 kỳ
- CEO-to-Median-Employee Pay Ratio (×)8 kỳ
- Annual Healthcare System Savings from Teva Generic Medicines — United States3 kỳ
- Scope 1 + Scope 2 (Market-Based) Greenhouse Gas Emissions (SLB KPI 2)8 kỳ
- Total Energy Consumption (MWh)3 kỳ
- Total Water Withdrawal (Megaliters)3 kỳ
- Total Waste Generated (Metric Tons)6 kỳ
- Global Health Authority GMP & Quality Regulatory Inspections8 kỳ
- Employee Total Recordable Injury Frequency Rate (TRIFR)8 kỳ
- Women as a Share of Global Workforce (%) (%)3 kỳ
U.S. Pharmaceutical Industry Pricing & Demand Benchmarks (BLS / Census / BEA)
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (NAICS 325412)105 kỳ
- U.S. Consumer Price Index — Medicinal Drugs (All Urban Consumers)104 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores (Seasonally Adjusted) ($M)104 kỳ
- U.S. Real Personal Consumption Expenditures — Pharmaceutical and Other Medical Products (SAAR)35 kỳ
Database Segment & Consolidated GAAP Financial Statement Baseline
- Database Segment Baseline — United States / North America Revenue ($M)15 kỳ
- Database Segment Baseline — Europe Revenue ($M)36 kỳ
- Database Segment Baseline — International Markets Revenue ($M)38 kỳ
- Database Segment Baseline — Other Activities Revenue ($M)38 kỳ
- GAAP Consolidated Revenues ($M)75 kỳ
- GAAP Total Assets ($M)43 kỳ
- GAAP Total Liabilities ($M)43 kỳ
- GAAP Total Equity (Including Non-Controlling Interests) ($M)44 kỳ
- GAAP Net Cash Provided by / (Used in) Operating Activities ($M)43 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Teva Pharmaceutical Industries
- SEC Form 10-Q (0000818686-26-000006) ↗
- SEC Form 10-K (0001193125-26-034532) ↗
- Form 8-K Earnings Release (0001171843-26-007054) ↗
- Teva Investor Relations / ESG (teva esg progress report disclosures 2025) ↗
- Form 10-K (0001193125-26-034532) ↗
- SEC Filing (0000818686-26-000006) ↗
- Form 8-K Earnings Release (0001171843-26-000462) ↗
- SEC Form 10-K (0001193125-24-031005) ↗
- SEC Filing (0001193125-26-134756) ↗
- Federal Reserve Economic Data (FRED: PCU325412325412) ↗
- Federal Reserve Economic Data (FRED: CUSR0000SAM1) ↗
- Federal Reserve Economic Data (FRED: MRTSSM44611USS) ↗
See a number that looks wrong?